Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for tough liver cancer cases

NCT ID NCT06233981

Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new treatment for advanced liver cancer that has spread into the major blood vessels of the liver. Thirty patients received a special type of radiation along with an immunotherapy drug called tislelizumab. The goal was to see if this combination could help patients live longer and shrink their tumors. Patients continued on maintenance therapy until their disease got worse or side effects became too much.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

30 people

The number who actually took part.

Started

Jan 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Clinical or histological diagnosis of HCC with bilateral PVTT; 2. Estimated Liver-GTV volume \< 700ml or the estimated volume of liver minus GTV volume receiving less than 5 Gy of irradiation \< 300ml; 3. Age 18-90 years; 4. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1; 5. Child-Pugh A5, A6, B7 and B8; 6. Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 times upper limit of normal (ULN); or ALT ≤ 1.5 times ULN and AST ≤ 6 times ULN; TBIL \< 60umol/L. 7. Creatinine (CRE) and blood urea nitrogen (BUN) \< 2.5 ULN; 8. Hb ≥ 50g/L, ANC ≥ 0.5 × 109/L, PLT ≥ 30 × 109 /L; patients with a history of gastrointestinal bleeding must be controlled for more than 2 weeks before enrollment with Hb ≥ 60g/L; 10\. Voluntary to participate and sign informed consent. Exclusion Criteria: 1. Participating in other clinical trials currently; 2. The history of abdominal irradiation; 3. The history of liver transplantation; 4. Known allergy to tislelizumab or lenvatinib; 5. Pregnant, breast feeding, or unwilling to use adequate contraception; 6. Serious myocardial disease or renal failure; 7. Other serious diseases, such as alcohol and drug abuse or mental illness; 8. Presence of other life-threatening malignancy within the last 3 years before enrollment (excluding superficial skin cancer, localized low-grade malignant tumor and carcinoma in situ).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma Radiotherapy Tislelizumab Tumor thrombosis

Contacts and locations

Locations

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciecnces and Peking Union Medical College

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.